Abiopharma

🔍 Cooper Ellen (Director)

Company: Cencora, Inc. (COR)

Report Date: 2026-01-30

Detailed Transactions and Holdings:

• Acquired 69 shares of Common Stock at $359.22 per share (Direct)
  Date: 2026-01-30 | Code: A | equity_swap_involved: 0 | shares_owned_after: 74.00 | transaction_form_type: 4 | Footnotes: F1
• Acquired 66 shares of Common Stock at $359.22 per share (Direct)
  Date: 2026-01-30 | Code: A | equity_swap_involved: 0 | shares_owned_after: 140.00 | transaction_form_type: 4 | Footnotes: F3
• Acquired 557 shares of Common Stock at $359.28 per share (Direct)
  Date: 2026-03-05 | Code: A | equity_swap_involved: 0 | shares_owned_after: 697.00 | transaction_form_type: 4 | Footnotes: F4

Footnotes:

• F1: Pro-rated annual grant of restricted stock units in connection with Ms. Cooper's appointment to the Board on January 20, 2026, received for no consideration and vests 100% on the first anniversary of the date of the grant. Receipt of shares deferred until cessation of service.
• F2: Includes 5 shares of common stock owned by Ms. Cooper on January 20, 2026, the date of Ms. Cooper's appointment to the Board.
• F3: Grant of restricted stock units received in lieu of quarterly cash retainer per the Registrant's Non-Employee Director Compensation Program, pro-rated in connection with Ms. Cooper's appointment to the Board on January 20, 2026. Receipt of shares deferred until cessation of service.
• F4: Annual grant of restricted stock units received for no consideration and vests 100% on the first anniversary of the date of the grant. Receipt of shares deferred until cessation of service.